Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and
account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively …

Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX
1, 2, or 4. With approximately 800 to 1,000 cases a year in the United States, it most …

Purpose: The impact of different local therapy approaches on local control, event-free
survival, and secondary malignancies in the CESS 81, CESS 86, and EICESS 92 trials was …

This paper describes the standard of care for patients with non-rhabdomyosarcoma soft
tissue sarcomas (NRSTS) and the therapeutic recommendations developed by the …

Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag
behind those of children diagnosed with histologically similar tumours. To help understand …

Soft-tissue sarcomas in children comprise a heterogeneous group of entities with variable
manifestation depending on the age of the patient and the location of the tumor. MRI is the …

The SMARCB1 gene (INI1, BAF47) is a member of the SWItch/Sucrose Non-Fermentable
(SWI/SNF) chromatin remodeling complex, involved in the epigenetic regulation of gene …

Opinion Statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue
sarcoma (STS), for which survival has not improved significantly during the past years. In this …

Background A standardised approach to treatment of paediatric non-rhabdomyosarcoma
soft tissue sarcomas (NRSTS), which account for about 4% of childhood cancers, is still …

Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft
tissue sarcomas. Although it can occur at any age, it typically affects younger adults and …